Product Line Growth:
Launch of the 24/7 AI agent “Billie” in 2025 and the 2026 addition of pre‑service automation via the Pledge Health acquisition indicate a broadening product portfolio across the revenue cycle. These moves suggest continued R&D velocity and expansion into adjacent workflows.
Strategic Partnerships:
Preferred‑partner status with CentralReach and newly announced financing and distribution partnerships point to expanding channels and ecosystem reach. Such relationships can accelerate adoption within specialized provider segments.
Investor Backing & Capital Strength:
A $29M Series A round in 2023 and the capacity to complete an acquisition in 2026 reflect access to growth capital. These signals indicate financial support for scaling product and go‑to‑market efforts.
